Abstract

Case Report

Cystoid Macular Oedema Secondary to Bimatoprost in a Patient with Primary Open Angle Glaucoma

Konstantinos Kyratzoglou* and Katie Morton

Published: 07 April, 2025 | Volume 9 - Issue 1 | Pages: 001-003

Cystoid Macular Oedema (CMO) is a condition characterized by fluid accumulation in the macular region of the retina, leading to the formation of cyst-like spaces. This edema often results in visual impairment and is associated with various ocular and systemic conditions, including surgery, inflammation, or medication use. 
The authors present a case where Cystoid Macular Oedema (CMO) occurred after commencing topical bimatoprost in a pseudophakic patient with primary open angle glaucoma. The macular oedema was treated effectively with a combination of non-steroidal and steroidal topical drops. This case report shows a possible correlation between bimatoprost and CMO, in a patient with no recent confounding risk factors known to contribute to CMO . The recommendation from this report is that all patients treated with topical bimatoprost drops should have a baseline macula OCT examination and a repeated OCT examination 8 weeks after initiation of treatment, to facilitate early detection of CMO.

Read Full Article HTML DOI: 10.29328/journal.ijceo.1001059 Cite this Article Read Full Article PDF

Keywords:

Bimatoprost; Primary open angle glaucoma; Pseudophakic; Cystoid macular oedema

References

  1. Wagner IV, Stewart MW, Dorairaj SK. Updates on the diagnosis and management of glaucoma. Mayo Clin Proc Innov Qual Outcomes. 2022;6(6):618–635. Available from: https://doi.org/10.1016/j.mayocpiqo.2022.09.007
  2. National Institute for Health and Care Excellence (NICE). Glaucoma: Diagnosis and Management [Internet]. NICE guideline NG81; 2017 [updated 2022 Jan 26]. Available from: https://www.nice.org.uk/guidance/ng81
  3. Awwad AM, El Sobky HM, Mandour SS. Study of the effect of prostaglandin analogs on the Periorbita of glaucomatous patients. Menoufia Med J. 2022;35(4):2027. Available from: https://doi.org/10.4103/mmj.mmj_255_22
  4. Katsanos A, Riva I, Bozkurt B, Holló G, Quaranta L, Oddone F, et al. A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opin Drug Saf. 2021;21(4):525–539. Available from: https://doi.org/10.1080/14740338.2022.1996560
  5. Schilling S, Brobst C, Joondeph BC. An elusive case of cystoid macular edema. Retina Today [Internet]. 2021 Apr:50–51. Available from: https://retinatoday.com/articles/2021-apr/an-elusive-case-of-cystoid-macular-edema
  6. Zhou Y, Bicket AK, Marwah S, Stein JD, Kishor KS. Incidence of acute cystoid macular edema after starting a prostaglandin analog compared with other classes of glaucoma medications. Ophthalmol Glaucoma. 2025;8(1):4–11. Available from: https://doi.org/10.1016/j.ogla.2024.07.010
  7. Hu J, Vu JT, Hong B, Gottlieb C. Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2020;104(8):1040–1044. Available from: https://doi.org/10.1136/bjophthalmol-2019-315280
  8. Reddy S, Sahay P, Padhy D, Sarangi S, Suar M, Modak R, et al. Tear biomarkers in Latanoprost and bimatoprost treated eyes. PLoS One. 2018;13(8):e0201740. Available from: https://doi.org/10.1371/journal.pone.0201740

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?